Clinigen Group plc (LSE: CLIN) has acquired Cardioxane from healthcare product company Novartis Corp. (NYSE: NVS) for $33 million in cash.

Cardioxane is used to treat breast cancer patients.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.